LENZ Therapeutics (NASDAQ:LENZ) Price Target Raised to $47.00 at Citigroup

LENZ Therapeutics (NASDAQ:LENZ) had its price target lifted by Citigroup from $44.00 to $47.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, TD Cowen started coverage on LENZ Therapeutics in a research note on Tuesday. They set a “buy” rating and a $60.00 price target for the company. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, LENZ Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $41.67.

LENZ Therapeutics Stock Performance

Shares of NASDAQ LENZ opened at $26.30 on Thursday. LENZ Therapeutics has a one year low of $14.42 and a one year high of $38.93. The company’s fifty day moving average is $24.09 and its two-hundred day moving average is $27.01.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.04). On average, equities analysts predict that LENZ Therapeutics will post -2.18 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in LENZ Therapeutics in the 4th quarter valued at about $29,000. KLP Kapitalforvaltning AS acquired a new position in LENZ Therapeutics in the 4th quarter valued at about $46,000. Tower Research Capital LLC TRC raised its stake in LENZ Therapeutics by 162.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company’s stock valued at $54,000 after purchasing an additional 1,151 shares during the last quarter. Virtus ETF Advisers LLC acquired a new position in LENZ Therapeutics in the 4th quarter valued at about $67,000. Finally, SG Americas Securities LLC raised its stake in LENZ Therapeutics by 20.7% in the 4th quarter. SG Americas Securities LLC now owns 5,458 shares of the company’s stock valued at $158,000 after purchasing an additional 935 shares during the last quarter. Institutional investors and hedge funds own 54.32% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.